Table 2.

The most important direct-acting antivirals for HBV under development.

Category	Compound	Development Status	Reference
Entry inhibitors	Myrcludex-B	Phase III	[109,112]
	Cyclosporin A	Preclinical	[113,114,115]
	CRV431	Phase I	[118]
cccDNA formation inhibitors/inactivators	TALENs	Preclinical	[119]
	CRISPR/Cas9	Preclinical	[120,121,122,123]
Capsid assembly inhibitors/modulators	BAY 41-4109	Phase I	[109]
	GLS-4	Phase II	[124]
	NVR 3-778	Phase IIa	[125,126]
	JNJ-6379	Phase III	[127]
	ABI-H0731	Phase IIa	[128]
RNA interference	ARC-520	Phase II	[109,129]
	JNJ-3989	Phase I/II	[109,129]
	AB-729	Phase I	[109,129]
HBsAg secretion inhibitors	REP 2139	Phase II	[130]
	REP 2165	Phase II	[130]
Ribonuclease H inhibitors	HPD 208	Preclinical	[131]
	αHT 110	Preclinical	[131]